Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for several types of cancer. However, the shortcomings of PD-1/PD-L1 inhibitors have been observed, i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematol Oncol
Asıl Yazarlar: Wang, Dongxu, Lin, Jianzhen, Yang, Xu, Long, Junyu, Bai, Yi, Yang, Xiaobo, Mao, Yilei, Sang, Xinting, Seery, Samuel, Zhao, Haitao
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6480748/
https://ncbi.nlm.nih.gov/pubmed/31014381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0730-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller